{"id":390096,"date":"2021-03-01T00:00:00","date_gmt":"2021-03-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2020-biopharma-colorectal-cancer-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-05-04T23:22:39","modified_gmt":"2026-05-04T23:22:39","slug":"dlsfon0002-2020-biopharma-colorectal-cancer-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2020-biopharma-colorectal-cancer-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Colorectal Cancer | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>Targeted therapies and various biomarkers (e.g., <em>RAS<\/em>, <em>BRAF<\/em>, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented by the side on which the tumor is located, <em>BRAF<\/em> status, and MSI-H or dMMR status. Immune checkpoint inhibitors targeting MSI-H \/ dMMR metastatic colorectal cancer are experiencing uptake and influencing current treatment algorithms. Therapies targeting specific biomarker-defined populations, such as <em>BRAF<\/em>-mutant metastatic colorectal, contribute to more-personalized treatment. This report provides insight on how treatment options for colorectal cancer are likely to change over the 2019-2029 forecast period. It also analyzes the current and future earnings potential of drugs already in the market and those expected to be approved for colorectal cancer.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>Current treatment for metastatic colorectal cancer is dominated by chemotherapy regimens in combination with angiogenesis inhibitors and EGFR inhibitors. The launch of new, high-priced therapies for colorectal cancer will encounter competition from generic and biosimilar versions of older therapies. <strong>What are the key drivers of and constraints on the colorectal cancer therapy market, and how will the major markets evolve over the 10-year forecast period? What are the drug development activities of note? What challenges and opportunities remain?<\/strong><\/li>\n<li>The BRAF inhibitor combination of Braftovi plus Erbitux has shown promising efficacy in <em>BRAF<\/em>-mutant colorectal cancer patients. <strong>What is thought-leader opinion of this combination? For which lines of therapy will this combination be positioned? How will use of this combination affect prescribing of other agents for colorectal cancer?<\/strong><\/li>\n<li>Keytruda (Merck &#038; Co.) was approved in the United States in 2020 and in Europe in 2021 for the first-line treatment of MSI-H\/dMMR metastatic colorectal cancer. This agent and Opdivo\u2014with or without low-dose Yervoy (Bristol Myers Squibb)\u2014have been available since 2017 in the United States and in Japan since 2020 for the second- and later-line treatment of MSI-H\/dMMR colorectal cancer\u00a0refractory to a fluoropyrimidine, irinotecan, and oxaliplatin.\u00a0<strong>How do key opinion leaders perceive these therapies? Will these therapies receive label expansions? Which other immune checkpoint inhibitors are being developed and for which patient populations?<\/strong><\/li>\n<li>Retrospective analyses of clinical trials with Avastin and EGFR inhibitors have shown that the side on which the tumor is located could be a prognostic factor for response to these agents. <strong>How do key opinion leaders view these data? Will \u201csidedness\u201d influence the treatment of metastatic colorectal cancer during the forecast period?<\/strong><\/li>\n<\/ul>\n<p><strong>Scope: <\/strong><\/p>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><strong>Primary research:<\/strong> 20 country-specific interviews with thought leaders.<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed incident cases of stage I, II, III, and IV colorectal cancer.<\/p>\n<p><strong>Population segments in market forecast<\/strong>:Stage II colon cancer;stage II rectal cancer;stage III colon cancer;stage III rectal cancer;stage IV colorectal cancer wild-type <em>BRAF<\/em> and <em>RAS,<\/em> first-line (left-sided);stage IV colorectal cancer wild-type <em>BRAF<\/em> and <em>RAS,<\/em> first-line (right-sided);stage IV colorectal cancer mutant <em>RAS,<\/em> first-line;stage IV colorectal cancer mutant <em><em>BRAF<\/em>,<\/em> first-line;stage IV colorectal cancer wild-type <em>BRAF<\/em> and <em>RAS<\/em><em>,<\/em><em>\u00a0<\/em>second-line (left-sided); stage IV colorectal cancer wild-type <em>BRAF<\/em> and <em>RAS<\/em><em>,<\/em><em>\u00a0<\/em>second-line (right-sided); stage IV colorectal cancer mutant <em>RAS<\/em>, second-line; stage IV colorectal cancer mutant <em><em>BRAF<\/em><\/em>, second-line; stage IV colorectal cancer wild-type <em>BRAF<\/em> and <em>RAS<\/em><em>,<\/em> third-line (left-sided); stage IV colorectal cancer wild-type <em>BRAF<\/em> and <em>RAS<\/em><em>,<\/em> third-line (right-sided); stage IV colorectal cancer mutant <em>RAS,<\/em> third-line; stage IV colorectal cancer mutant <em><em>BRAF<\/em><\/em>.<\/p>\n<p><strong>Emerging therapies:<\/strong> Phase III: 7 drugs; Phase I-II: 9 drugs.<\/p>\n","protected":false},"template":"","class_list":["post-390096","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-colorectal-cancer","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390096\/revisions"}],"predecessor-version":[{"id":576443,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390096\/revisions\/576443"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}